Priority 8 from the Sight Loss and Vision PSP Age Related Macular Degeneration

UNCERTAINTY: Can a non-invasive therapy be developed for wet age related macular degeneration (AMD)? (JLA PSP Priority 8)

Overall ranking 8
JLA question ID 0014a/8
Explanatory note No relevant systematic reviews identified at the time of the PSP
Evidence No evidence at the time of the PSP
Health Research Classification System category Eye
Extra information provided by this PSP
Original uncertainty examples None provided
Systematic reviews that need updating or extending None identified
Systematic reviews in preparation (at time of PSP) Williams MA, McKay GJ, Chakravarthy U. Complement inhibitors for age-related macular degeneration (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 9. Art. No.: CD009300. DOI: 10.1002/14651858.CD009300 (in preparation at time of PSP)
Ongoing controlled trials

Enrichment of macular pigment in subjects with age-related macular degeneration (AMD) ISRCTN13894787

Enhancing the therapeutic efficacy of sleep deprivation by modafinil - a double blind, randomized, placebo-controlled, monocentric phase II study https://www.clinicaltrialsregister.eu/ctr-search/search? query=eudract_number:2005-003196-21
Submitted by Patients
Outcomes to be measured Change or management of in symptoms; adverse effects or complications; acceptability to the patient; and cost
PSP information
PSP unique ID 0014a
PSP name Sight Loss and Vision - Age Related Macular Degeneration
Total number of uncertainties identified by this PSP. 113  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop April and May 2013